Reviva Pharmaceuticals Holdings, Inc. Shareholders' Equity
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Shareholders' Equity of $15.21 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $15.21M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $17.44M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $8.65M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $4.55M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $15.21M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $17.44M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $8.65M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $4.55M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$459.15K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | -$4.46M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $812.57K 10-Q · filed 2026-08-12 | |
| 2024-09-30 | -$9.98M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$6.04M 10-Q · filed 2025-11-13 | |
| 2024-03-31 | -$1.35M 10-Q · filed 2025-08-14 | |
| 2023-12-31 | $5.72M 10-K · filed 2026-03-30 | |
| 2023-09-30 | -$12.81M 10-Q · filed 2024-11-14 | -$8.52M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$1.82M 10-Q · filed 2024-11-14 | $1.62M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.61M 10-Q · filed 2024-08-14 | $5.78M 10-Q · filed 2023-05-15 |
| 2023-01-01 | $8.39M 10-K · filed 2025-04-03 | |
| 2022-12-31 | $8.39M 10-Q · filed 2024-11-14 | $12.32M 10-K · filed 2023-03-30 |
| 2022-09-30 | $17.56M 10-K · filed 2024-04-15 | $20.36M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $16.06M 10-Q · filed 2023-11-14 | |
| 2022-03-31 | $21.36M 10-Q · filed 2023-08-14 | |
| 2021-12-31 | $28.69M 10-K · filed 2024-04-15 | |
| 2021-09-30 | $32.27M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $34.52M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $4.52M 10-Q · filed 2022-08-15 | |
| 2020-12-31 | $5.47M 10-K · filed 2023-03-30 | $7.43M 10-K · filed 2021-03-22 |
| 2020-11-30 | $5.00M 10-Q · filed 2021-01-14 | |
| 2020-09-30 | -$8.65M 10-Q · filed 2021-11-15 | |
| 2020-08-31 | $5.00M 10-Q · filed 2020-10-14 | |
| 2020-06-30 | -$8.41M 10-Q · filed 2021-11-15 | |
| 2020-05-31 | $5.00M 10-Q · filed 2020-07-07 | |
| 2020-03-31 | -$7.56M 10-Q · filed 2021-08-16 | |
| 2020-02-29 | $5.00M 10-Q · filed 2021-01-14 | |
| 2019-12-31 | -$6.81M 10-K · filed 2022-03-15 | |
| 2019-11-30 | $5.00M 10-Q · filed 2020-01-10 | |
| 2019-08-31 | $5.00M 10-Q · filed 2019-10-08 | |
| 2019-05-31 | $5.00M 10-Q · filed 2019-07-03 | |
| 2019-02-28 | $5.00M 10-K · filed 2020-05-04 | |
| 2018-12-31 | -$5.96M 10-K/A · filed 2021-05-07 | |
| 2018-11-30 | $5.00M 10-Q · filed 2019-01-09 | |
| 2018-08-31 | $5.00M 10-Q · filed 2018-10-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |